1. Delgocitinib cream was more effective and safer than oral alitretinoin in treating severe chronic hand eczema.
2. Delgocitinib showed a significantly greater reduction in Hand Eczema Severity Index scores at week 12.
3. More patients in the delgocitinib group achieved at least a 90% improvement in HECSI scores.
4. Delgocitinib provided greater relief from itch and pain compared to alitretinoin.
5. Delgocitinib is a nonsteroidal topical pan–Janus kinase (JAK) inhibitor targeting multiple inflammatory pathways.
6. The study supports delgocitinib cream as a potential nonsystemic treatment alternative for severe chronic hand eczema.

Source: The Lancet